• Syringin Workflow for RCC Combination Research

  2026-08-18

  Syringin offers a practical natural-product entry point for RCC phenotypic screening, apoptosis research, and sunitinib-sensitization studies. This workflow connects solvent-controlled dose testing with EGFR/PI3K/Akt pathway validation, helping researchers distinguish genuine combination effects from assay artifacts.

• DiI (DiIC18(3)) Plasma Membrane Probe Guide

  2026-08-18

  DiI (DiIC18(3)) provides orange-red labeling of plasma membranes in live or fixed cells and tissues, supporting neuronal tracing, migration, adhesion, fusion, and lipoprotein workflows. It is water-insoluble and should not be treated as a general cytoplasmic or organelle stain; solvent selection, membrane integrity, fixation, and imaging controls are essential.

• ONX-0914: Immunoproteasome Biology Beyond the Cell

  2026-08-17

  ONX-0914 (PR-957) is a selective LMP7 inhibitor for dissecting cytokine signaling and immunoproteasome function. This article adds an extracellular-vesicle perspective, showing how intercellular proteasome transfer can influence assay interpretation in autoimmune, arthritis, and diabetes research.

• MG-262: Reversible Proteasome Inhibitor

  2026-08-17

  MG-262, also called Z-Leu-Leu-Leu-B(OH)2, is a reversible, cell-permeable boronic peptide acid that inhibits proteasome chymotryptic activity. It provides a controlled perturbation tool for proteasome inhibition assay design, apoptosis research, and studies connecting ubiquitin-dependent degradation with skeletal muscle proteostasis.

• ONX-0914 (PR-957) Workflow for Immune Assays

  2026-08-16

  ONX-0914 (PR-957) enables selective LMP7-focused immunoproteasome inhibition for cytokine, PBMC, and autoimmune disease model workflows. This guide combines practical dosing, assay controls, and troubleshooting with a cautious neuroimmune bridge inspired by cortical synaptic research.

• ONX-0914: From LMP7 Selectivity to CNS Assays

  2026-08-15

  ONX-0914 (PR-957) is best known for selective immunoproteasome inhibition in autoimmune models. This article develops a distinct assay-centered framework linking LMP7 target engagement, cytokine production blockade, chronic exposure, and hippocampal synaptic-plasticity measurements.

• JNJ-26854165 (Serdemetan) Assay Workflows

  2026-08-14

  Build more informative p53-pathway experiments with JNJ-26854165 (Serdemetan), combining growth-inhibition measurements with apoptosis-specific and radiation-response readouts. This workflow separates cytostatic effects from true cell killing while addressing solubility, timing, genotype, and assay-design challenges.

• MG-262 for Muscle Proteostasis Assay Design

  2026-08-14

  MG-262 and Z-Leu-Leu-Leu-B(OH)2 provide a reversible, cell-permeable way to interrogate proteasome function without confusing it with chaperone-mediated autophagy. This guide translates new skeletal-muscle CMA findings into more rigorous proteasome inhibition assay design and interpretation.

• Necrosulfonamide: MLKL Inhibition in Necroptosis

  2026-08-13

  Necrosulfonamide (NSA) is a selective MLKL inhibitor for mechanistic necroptosis assays and cell death pathway research. Product information reports approximately 124 nM protection of HT-29 cells from induced necroptosis, while Liu et al. connect necroptosis to peroxynitrite-driven calcium dysregulation in cardiac microvascular ischemia–reperfusion injury.

• MLN2238: Proteasome β5 Subunit Inhibitor Workflows

  2026-08-13

  MLN2238 enables controlled, reversible chymotrypsin-like proteasome inhibition for apoptosis, drug-resistance, and proteotoxic-stress studies. This workflow-centered guide connects β5-site pharmacology with CREB/CRTC stress signaling while addressing solubility, dosing, and assay-interpretation challenges.

• One-step TUNEL FITC Apoptosis Detection Kit

  2026-08-12

  Translate omics-defined reproductive toxicity into a spatially resolved DNA fragmentation assay for testis sections, with parallel validation in cultured cells and flow cytometry. This workflow combines practical controls, quantitative imaging, and troubleshooting guidance for interpreting apoptosis-associated signal without overstating mechanism.

• TLS–CD40–STING Signaling in ESCC B Cells

  2026-08-12

  The reference study links tertiary lymphoid structures with favorable outcomes in treatment-naïve esophageal squamous cell carcinoma and identifies IRF4-positive B cells as a central immune feature. Its mechanistic model proposes that CD40 and STING compete for TRAF2, thereby coordinating non-canonical NF-κB signaling, STING modification, and B-cell activation.

• PLAC1 in ccRCC: Biomarker and Target Evidence

  2026-08-11

  The reference study identifies placenta-specific protein 1 (PLAC1) as an overexpressed, adverse prognostic marker in clear cell renal cell carcinoma and combines loss-of-function experiments with high-throughput virtual screening. Its identification of Amaronol B and canagliflozin as compounds that reduce PLAC1 expression provides a hypothesis-generating route toward biomarker-guided therapeutic research.

• PXR Activation, Liver Regeneration, and CYP Activity

  2026-08-11

  Bi et al. show that pharmacological activation of pregnane X receptor in rats increases liver mass and supports regeneration while enhancing CYP3A1/2 and CYP2C6/11 expression and metabolic activity. The study separates structural hepatic adaptation from functional drug metabolism and provides a useful framework for interpreting PXR responses after liver injury.

• CTCF Safeguards Centromere Function and Mitosis

  2026-08-10

  The reference study uses rapid, inducible CTCF degradation to show that CTCF maintains centromere mechanics, chromosome alignment, mitotic fidelity, and post-mitotic nuclear shape. Its findings distinguish CTCF-dependent centromere maintenance from CENP-E recruitment and provide a framework for interpreting mitotic perturbation experiments in cancer research.

16963 records 1/1131 page Next 12345 下5页 Last page